Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Peringkat dalam Saham #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Harga Saham
$58.70
Terakhir disinkronkan: 2024-01-23
Kapitalisasi Pasar
$2.98B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Mirati Therapeutics, Inc. (MRTX)

Kategori

Riwayat harga saham Mirati Therapeutics, Inc. (MRTX)
Harga penutupan tertinggi: $58.94 pada 2024-01-01

Harga penutupan terendah: $8.67 pada 2013-07-01
Riwayat harga saham Mirati Therapeutics, Inc. dari 2013 hingga 2026
Performa harga saham tahunan
Tahun Performa
2024 2.02%
2023 12.06%
2022 -63.56%
2021 -39.15%
2020 103.16%
2019 189.49%
2018 132.29%
2017 218.41%
2016 -84.08%
2015 98.82%
2014 1.02%
2013 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.41 -12.81%
AU
$764.47 7.08%
CH